An Open Label Multi-Dose-Escalation, Safety and Pharmacokinetic Study of SAR3419 Administered As a Single Agent by Intravenous Infusion Every 3 Weeks in Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL).

Trial Profile

An Open Label Multi-Dose-Escalation, Safety and Pharmacokinetic Study of SAR3419 Administered As a Single Agent by Intravenous Infusion Every 3 Weeks in Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL).

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Feb 2012

At a glance

  • Drugs Coltuximab ravtansine (Primary)
  • Indications B cell lymphoma
  • Focus Adverse reactions
  • Sponsors Sanofi
  • Most Recent Events

    • 13 Feb 2012 Actual patient number 39 added as reported by ClinicalTrials.gov.
    • 13 Feb 2012 Actual patient number 39 added as reported by ClinicalTrials.gov.
    • 13 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top